Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder_老虎社区_美港股上老虎

Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder

seekingalpha2022-02-07

The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Betterjob
·2022-02-07
Good news
回复
2
举报
收起
- indietro_:
  Ok
  2022-02-07
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2209378762?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-02-07 18:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2209378762","market":"us","top_or_hot":-1,"title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","media":"seekingalpha","content":"<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","article_id":"2209378762","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","pubTimestamp":1644231186,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药"},"translate_title":"赛诺菲的Enjaymo获得美国FDA罕见血液疾病批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9},"content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":633526654,"gmtCreate":1644233120905,"gmtModify":1644233121084,"author":{"id":"4087549167151930","authorId":"4087549167151930","name":"Betterjob","avatar":"https://static.tigerbbs.com/3a6e660c283e305dd2a1669316c2511b","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/633526654","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","pubTimestamp":1644231186,"share":"https://www.laohu8.com/m/news/2209378762?lang=&edition=full","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7233629,"gmtCreate":1644234252474,"gmtModify":1644234252585,"authorId":3586255748151463,"author":{"id":3586255748151463,"authorId":3586255748151463,"name":"indietro_","avatar":"https://static.tigerbbs.com/caebb6c2a70cbd2db563a3808f3d7b22","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633526654,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}